Thailand Genomic Policy: Rare Disease Diagnosis Cut to 5 Days
Prof. Dr. Vorasuk Shotelersuk highlights the breakthrough of NGS genomic diagnosis at Techsauce Global Summit 2026, pushing toward national coverage.
Stock photo for illustration only, not from the actual event
- Next-Generation Sequencing (NGS) cuts rare disease diagnosis time from 4-5 years to just 5 days.
- Over 7,000 rare diseases affect approximately 5% of Thailand's population, totaling 2 to 3.5 million people.
- Chulalongkorn University connects 9 medical centers in Thailand and 8 APAC institutions via the INSPIRE Consortium.
- The core challenge remains integrating existing healthcare infrastructure under the universal coverage scheme.
The contrasting fates of two children born in the same year highlight deep disparities in accessing advanced medical care. Freddie, born in the UK, underwent newborn genomic screening before showing any symptoms, allowing doctors to detect an early-stage retinoblastoma and preserve his vision. Conversely, a young Thai girl arrived at a hospital at 1 year and 7 months old with massive tumors in both eyes, leaving surgeons with no choice but to remove both eyeballs to save her life.
Prof. Dr. Vorasuk Shotelersuk, Director of the Center of Excellence for Medical Genetics at Chulalongkorn University, shared these cases during the panel discussion titled Advancing Precision Diagnostics to Enable a National Rare Diseases Policy for Thailand at the Techsauce Global Summit 2026. The panel also featured Dr. Panadda Tepaksorn, Expert Medical Scientist at the Department of Medical Sciences, Ministry of Public Health, and Ms. Somrasa Pongpermpruek, Corporate Affairs Director at AstraZeneca (Thailand) Co., Ltd., with Dr. Kanapon Phumratanaprapin, CEO of Health at Home, serving as the moderator.
All three experts agreed that the technical tools and high-standard laboratories are already established in Thailand. The missing piece is a unified patient pathway connecting symptom onset to definitive treatment—or ideally, screening asymptomatic individuals carrying genetic mutations to prevent disease onset altogether.
Addressing policymakers' concerns over resource allocation for rare diseases, Prof. Dr. Vorasuk outlined three key arguments. First, while individual conditions are rare, over 7,000 combined rare diseases affect 3.5% to 5.9% of the global population—at least 300 million people, roughly seven times the global HIV population. In Thailand, the affected population stands at around 5%, or 2 to 3.5 million individuals. Second, 70% to 80% of rare diseases stem from complex genetic origins, with patients in remote areas historically facing 5 to 10 years of diagnostic delays or passing away undiagnosed. Third, modern Next-Generation Sequencing (NGS) technology now allows physicians to pinpoint genetic abnormalities in under a week.
"I do not think being born on Thai soil should be a disadvantage for this child. We must take action because the technology making a difference already exists; we just need to apply it."
Prof. Dr. Vorasuk Shotelersuk
Stock photo for illustration only, not from the actual event
A concrete example involves a one-month-old infant brought to King Chulalongkorn Memorial Hospital unconscious and on the brink of death without parental history of infection or toxins. The medical team performed whole-genome sequencing, yielding a diagnosis within five days of Cobalamin C Deficiency, a severe vitamin B12 metabolism disorder. Following targeted treatment, the infant regained normal developmental milestones by age four.
Integrating genomic sequencing at a national level marks a fundamental shift from reactive treatment to proactive preventive medicine. The primary challenge is no longer declining equipment costs, but rather cross-departmental data integration and health technology assessment (HTA) to ensure economic sustainability within national healthcare frameworks.
To expand access, the team established the Thailand Undiagnosed Diseases Network, linking nine core medical centers nationwide to process blood samples and report findings back to local physicians. Furthermore, February 2025 marked the launch of the International Nanopore Sequencing Partnership for Rare Disease Engagement (INSPIRE) Consortium in Bangkok, uniting institutions across eight Asia-Pacific countries.
Regarding universal coverage reimbursement, completed institutional and national research studies are currently undergoing Health Technology Assessment (HTA). The findings will determine cost-effectiveness for public healthcare spending, paving the way for Thai patients to access advanced genomic diagnostics under the national healthcare scheme in due course.
Source: Techsauce
Found something wrong in this article? Report an issue with this article
Comments
Leave a Comment